Entropy Neurodynamics Limited has released a press release.
Shareholder Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Plexaris product engineered to deliver anti-cancer drug
- March Quarterly Report and Appendix 4C
- PLEXOVAL I study disrupted by the Covid-19 response
- Appendix 4D and Interim Financial Report
- Cevaris testing shows positive results in bladder control
Later from Entropy Neurodynamics
- Added IP empowers Exopharms engineered exosome pipeline
- June Quarterly Report and Appendix 4C
- Appendix 4E and Annual Financial Report FY 2020
- Exopharm raises $10m in well supported Placement
- September Quarterly Report and Appendix 4C
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics